Lee Sang-Min, Booe Jason M, Pioszak Augen A
Department of Biochemistry and Molecular Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Department of Biochemistry and Molecular Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Eur J Pharmacol. 2015 Sep 15;763(Pt B):196-205. doi: 10.1016/j.ejphar.2015.05.013. Epub 2015 May 14.
The G protein-coupled receptor (GPCR) superfamily constitutes the largest collection of cell surface signaling proteins with approximately 800 members in the human genome. GPCRs regulate virtually all aspects of physiology and they are an important class of drug targets with ~30% of drugs on the market targeting a GPCR. Breakthroughs in GPCR structural biology in recent years have significantly expanded our understanding of GPCR structure and function and ushered in a new era of structure-based drug design for GPCRs. Crystal structures for nearly thirty distinct GPCRs are now available including receptors from each of the major classes, A, B, C, and F. These structures provide a foundation for understanding the molecular basis of GPCR pharmacology. Here, we review structural mechanisms of ligand recognition and selectivity of GPCRs with a focus on selected examples from classes A, B, and C, and we highlight major unresolved questions for future structural studies.
G蛋白偶联受体(GPCR)超家族是细胞表面信号蛋白中数量最多的一类,人类基因组中约有800个成员。GPCR几乎调节着生理学的各个方面,并且是一类重要的药物靶点,市场上约30%的药物靶向GPCR。近年来,GPCR结构生物学的突破显著扩展了我们对GPCR结构和功能的理解,并开创了基于结构的GPCR药物设计新时代。目前已有近30种不同GPCR的晶体结构,包括A、B、C和F类中的每一类受体。这些结构为理解GPCR药理学的分子基础提供了依据。在此,我们回顾GPCR配体识别和选择性的结构机制,重点关注A、B和C类中的选定实例,并突出未来结构研究中主要未解决的问题。